The Impact of FDA New Drug Approval on Abnormal Return of Nasdaq Biotech Stock
碩士 === 長庚大學 === 企業管理研究所 === 97 === We observe two kinds of stocks. One is the components of Nasdaq Biotechnology Index (hereafter, cNBI) and the other is components of Phlx Drug Index (hereafter, cRXS). This study use an event study methodology for calculating abnormal return (hereafter, AR) and cum...
Main Authors: | Po Chang Chen, 陳柏昌 |
---|---|
Other Authors: | Y. W. Shyu |
Format: | Others |
Published: |
2009
|
Online Access: | http://ndltd.ncl.edu.tw/handle/64978819916415095797 |
Similar Items
-
The Research on How Biotech Laws and FDA Approvals Affects Abnormal Returns in Biotech Firms
by: Yung-ChiehChen, et al.
Published: (2014) -
Stock Splits And The Impact On Abnormal Return : A Quantitative Research on Nasdaq Stockholm
by: Fausti, Giovanni, et al.
Published: (2021) -
Influence of Expected and Unexpected Events on Abnormal Returns of Stock Prices : An Example of Biotech Stocks in Taiwan.
by: Yu-Ting Ching, et al.
Published: (2005) -
THE EFFECT OF NASDAQ STOCK INDEX ON THE RETURN AND VOLATILITY OF TAIWAN STOCK INDEX
by: Min-Sheng Li, et al.
Published: (2000) -
Announcement Effect of Drug Approvals by FDA
by: Ting, Hsiu Wen, et al.
Published: (2008)